Resources
Our primary focus for decades has been to provide you with the best possible support and to improve our services to meet the needs of your cardiovascular patients. Recently, we have developed medications not only for patients who require anticoagulation but also for rare diseases like hypertrophic cardiomyopathy (HCM). That's why we offer a rich collection of materials to download and further information by clicking on the links below. Please don't hesitate to reach out to your BMS contact to learn more.
Resources
Your material order form to support your patients.
We provide you with brochures which focus on following themes:
- Brochure on Prevention of Strokes in Atrial Fibrillation (AF)
- Brochure on Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)
- Brochure on Prevention of Blood Clots after Hip or Knee Replacement Surgery
- Emergency Card
The power of 2: which DOAC (Direct Oral Anticoagulant) for which patient?
Apixaban vs. Rivaroxaban: What were the results in large independent real-world analyses?2#, 3
Latest
A-Z
Z-A
Material available as printed version. Please contact your BMS partner.
References are available upon request:
1. Deitelzweig S, et al. Clinical Impact of Switching or Continuation of Apixaban or Rivaroxaban among Patients with Non-Valvular Atrial Fibrillation. J. Clin. Med. 2024;13(4):1073; https://doi.org/10.3390/jcm13041073.
2. Ray W.A. et al. Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation. JAMA. 2021;326(23):2395-2404.
3. Van Es N. et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood (2014) 124 (12): 1968–1975.
#There are no head-to-head studies between DOACs, so direct comparisons of DOACs are not possible. Real-world analysis only allows for hypothesis generation.
08/2024 432-CH-2400011